Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro

Pralatrexate (Folotyn; PLX) and belinostat (Beleodaq; BLS) are registered for the treatment of patients with peripheral T-cell lymphoma (PTCL) and are being considered for other lymphomas. In this study we investigated whether BLS had the ability to potentiate the cytotoxicity of PLX. A panel of lym...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Cell Dev Biol
Main Authors: Peters, Godefridus J., van Gemert, Frank P. A., Kathmann, Ietje, Reddy, Guru, Cillessen, Saskia A. G. M., Jansen, Gerrit
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Cell and Developmental Biology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7581941/
https://ncbi.nlm.nih.gov/pubmed/33163492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcell.2020.577215
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados